Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Kong be ihua, Ph.D
Shandong University Qilu Hospital
Principal Investigator - Liu ji hong, Ph.D
Sun Yat-Sen University Cancer Center
Principal Investigator - Wu li ngying, Ph.D
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cancer Institute& Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
- Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
- Qilu Hospital of Shandong University
Jinan, Shandong, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2014
- Primary completion
- 31 Aug 2015
- Completion
- 31 Aug 2016
- Last update posted
- 5 Jun 2017
- Registered enrollment
- 30
- Registry id
- NCT02237690
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.